Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis By Ogkologos - June 18, 2026 241 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SENTRY study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Celebrating 20 Years of Cancer.Net: How We’ve Worked to Empower People... May 3, 2022 A Propensity Score Matched Study Supports the Use of Allogeneic HSCT... May 12, 2023 TRACERx EVO, a new programme to transform lung cancer research November 9, 2022 How to Discuss Your Goals of Care With Your Cancer Care... October 17, 2023 Load more HOT NEWS ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July FDA Approves Idecabtagene Vicleucel for Multiple Myeloma How to Safely Keep Up With Your Cancer Screening and Care... Low-Dose Aspirin Could be an Alternative to Colectomy for Preventing Colorectal...
